SF Healthcare Week: Biohaven CEO Vlad Coric talks degraders, ion channel programs, and ADCs

blonca9
Jan 15
1 min read

He describes updates given for the degrader programs targeting IgG, IgA nephropathy, and peripartum cardiomyopathy.. Plus, ion channel programs BHV-7000 and BHV-2100, and ADCs including TROP2.

Recent Posts

See All

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

SF Healthcare Week: Biohaven CEO Vlad Coric talks degraders, ion channel programs, and ADCs

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight